HU190714B - Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid - Google Patents

Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid Download PDF

Info

Publication number: HU190714B
Authority: HU; Hungary
Prior art keywords: active ingredient; nortriptyline; preparation; dibenzocycloheptadiene; antidepressant
Prior art date: 1982-03-22

Application number

HU83934A

Other languages

English (en)

Hungarian (hu)

Inventor

Jack Singer

W Robert Griffith

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-22

Filing date

1983-03-21

Publication date

1986-10-28

1983-03-21 Application filed by Sandoz Ag filed Critical Sandoz Ag

1986-10-28 Publication of HU190714B publication Critical patent/HU190714B/hu

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
230000001430 anti-depressive effect Effects 0.000 title claims abstract description 6
239000000935 antidepressant agent Substances 0.000 title claims abstract description 6
PJQCANLCUDUPRF-UHFFFAOYSA-N dibenzocycloheptene Chemical compound C1CC2=CC=CC=C2CC2=CC=CC=C12 PJQCANLCUDUPRF-UHFFFAOYSA-N 0.000 title claims abstract description 4
238000000034 method Methods 0.000 title claims description 15
230000008569 process Effects 0.000 title claims description 10
238000002360 preparation method Methods 0.000 title claims description 7
229940005513 antidepressants Drugs 0.000 title claims description 5
229960003133 ergot alkaloid Drugs 0.000 title abstract 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 8
150000003839 salts Chemical class 0.000 claims abstract description 8
239000004480 active ingredient Substances 0.000 claims description 23
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 14
229960001158 nortriptyline Drugs 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 7
239000012458 free base Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 2
229930013930 alkaloid Natural products 0.000 claims 1
150000003797 alkaloid derivatives Chemical class 0.000 claims 1
235000002020 sage Nutrition 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 8
229940123445 Tricyclic antidepressant Drugs 0.000 abstract description 2
PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 abstract description 2
SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 abstract description 2
229960004290 dihydroergocornine Drugs 0.000 abstract description 2
LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 abstract description 2
229960004318 dihydroergocristine Drugs 0.000 abstract description 2
229960002032 dihydroergocryptine Drugs 0.000 abstract description 2
239000003029 tricyclic antidepressant agent Substances 0.000 abstract description 2
238000011282 treatment Methods 0.000 description 13
239000003826 tablet Substances 0.000 description 9
239000002775 capsule Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 6
208000020401 Depressive disease Diseases 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
230000006872 improvement Effects 0.000 description 4
-1 3-methylaminopropylidene Chemical group 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
241000416162 Astragalus gummifer Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
FQHMMOGHDWAXDI-WUQHHHCFSA-N ergoloid mesylate Chemical compound CS(O)(=O)=O.C([C@H]1[C@]2(O)O3)CCN1C(=O)[C@H](C)N2C(=O)[C@]3(C(C)C)NC(=O)[C@H]1CN(C)[C@H](CC=2C3=C4C=CC=C3NC=2)[C@@H]4C1 FQHMMOGHDWAXDI-WUQHHHCFSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229920000591 gum Polymers 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940071285 nortriptyline 75 mg Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Psychiatry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HU83934A 1982-03-22 1983-03-21 Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid HU190714B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36046382A	1982-03-22	1982-03-22

Publications (1)

Publication Number	Publication Date
HU190714B true HU190714B (en)	1986-10-28

Family

ID=23418055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU83934A HU190714B (en)	1982-03-22	1983-03-21	Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid

Country Status (18)

Country	Link
JP (1)	JPS58174317A (fr)
AU (1)	AU1262283A (fr)
BE (1)	BE896170A (fr)
CA (1)	CA1197465A (fr)
CH (1)	CH652927A5 (fr)
DE (1)	DE3308855A1 (fr)
FR (1)	FR2527077B1 (fr)
GB (1)	GB2116843B (fr)
GR (1)	GR77165B (fr)
HU (1)	HU190714B (fr)
IL (1)	IL68184A (fr)
IT (1)	IT1163156B (fr)
NL (1)	NL8300986A (fr)
NZ (1)	NZ203632A (fr)
PH (1)	PH22086A (fr)
PT (1)	PT76417B (fr)
SE (1)	SE8301530L (fr)
ZA (1)	ZA832005B (fr)

1983
- 1983-03-10 CH CH1296/83A patent/CH652927A5/de not_active IP Right Cessation
- 1983-03-12 DE DE19833308855 patent/DE3308855A1/de not_active Withdrawn
- 1983-03-16 FR FR8304428A patent/FR2527077B1/fr not_active Expired
- 1983-03-16 BE BE1/10740A patent/BE896170A/fr not_active IP Right Cessation
- 1983-03-18 GR GR70832A patent/GR77165B/el unknown
- 1983-03-18 NL NL8300986A patent/NL8300986A/nl not_active Application Discontinuation
- 1983-03-18 JP JP58044528A patent/JPS58174317A/ja active Pending
- 1983-03-21 SE SE8301530A patent/SE8301530L/xx not_active Application Discontinuation
- 1983-03-21 HU HU83934A patent/HU190714B/hu unknown
- 1983-03-21 CA CA000424059A patent/CA1197465A/fr not_active Expired
- 1983-03-21 NZ NZ203632A patent/NZ203632A/en unknown
- 1983-03-21 PT PT76417A patent/PT76417B/pt unknown
- 1983-03-21 AU AU12622/83A patent/AU1262283A/en not_active Abandoned
- 1983-03-21 IT IT20186/83A patent/IT1163156B/it active
- 1983-03-21 IL IL68184A patent/IL68184A/xx unknown
- 1983-03-21 GB GB08307751A patent/GB2116843B/en not_active Expired
- 1983-03-22 ZA ZA832005A patent/ZA832005B/xx unknown
- 1983-06-01 PH PH28998A patent/PH22086A/en unknown

Also Published As

Publication number	Publication date
DE3308855A1 (de)	1983-09-29
IL68184A (en)	1986-04-29
JPS58174317A (ja)	1983-10-13
IT8320186A0 (it)	1983-03-21
CH652927A5 (de)	1985-12-13
GB2116843A (en)	1983-10-05
ZA832005B (en)	1984-11-28
NL8300986A (nl)	1983-10-17
PT76417A (en)	1983-04-01
IT1163156B (it)	1987-04-08
CA1197465A (fr)	1985-12-03
SE8301530L (sv)	1983-09-23
BE896170A (fr)	1983-09-16
FR2527077A1 (fr)	1983-11-25
IL68184A0 (en)	1983-06-15
NZ203632A (en)	1986-09-10
GB8307751D0 (en)	1983-04-27
SE8301530D0 (sv)	1983-03-21
FR2527077B1 (fr)	1986-08-22
PT76417B (en)	1985-12-16
PH22086A (en)	1988-05-20
AU1262283A (en)	1983-09-29
GB2116843B (en)	1986-01-15
GR77165B (fr)	1984-09-10

Publication	Publication Date	Title
KR100481254B1 (ko)	2005-09-12	미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물
AU2003227516B2 (en)	2008-03-20	A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US20100210626A1 (en)	2010-08-19	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
JPH06508836A (ja)	1994-10-06	光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
EP0664123A1 (fr)	1995-07-26	Inhibition de maladies auto-immunitaires
JPH07215865A (ja)	1995-08-15	閉経後女性の性欲を増進するための方法
CA2235747C (fr)	2006-01-03	Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
KR20010015918A (ko)	2001-02-26	안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
EP1605940A1 (fr)	2005-12-21	Methode permettant de traiter une deficience cognitive legere et de prevenir ou de retarder l'apparition la maladie d'alzheimer
EP0629400A1 (fr)	1994-12-21	Compositions contenant de l'idebenone pour le traitement de la maladie d'Alzheimer
WO2003082270A1 (fr)	2003-10-09	Procede destine au traitement de troubles cognitifs
US4481206A (en)	1984-11-06	Spiro succinimide derivative in the treatment of dementia of the Alzheimer type
US3954988A (en)	1976-05-04	Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects
MXPA01010904A (es)	2002-06-21	Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion del conjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos a
IE904084A1 (en)	1991-05-22	Treatment of depression
US4593031A (en)	1986-06-03	Method of treating depression
HU190714B (en)	1986-10-28	Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid
US7338955B1 (en)	2008-03-04	Medicament for treatment of neuropathies
KR20010105418A (ko)	2001-11-28	기분 장애 치료용 오사네턴트
JP2003523385A (ja)	2003-08-05	神経変性疾患の治療法
HU206623B (en)	1992-12-28	Process for producing pharmaceutical compositions containing imidazo-pyrrolo-benzodiazepine as antipsychotic active component
CA2426492C (fr)	2006-10-03	Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
WO1992007564A2 (fr)	1992-05-14	Procede de traitement des maladies demyelinisantes
US20060079513A1 (en)	2006-04-13	Methods and compositions including methscopolamine nitrate
IE54257B1 (en)	1989-08-02	Trans-dihydrolisuride antipsychotic